
Infectious Disease

LIAISON® Mumps IgG

The fully automated solution for quantitative antibody detection





Infectious Disease

LIAISON® Mumps IgG

	_		
		Number of tests	100
FEATURES		Method	Indirect Quantitative
		Assay range	5 – 300 AU / mL
		Solid Phase	Recombinant nucleoprotein expressed in P. pastoris
		Conjugate	MoAb to human IgG conjugated to isoluminol derivative
		Label	ABEI
		Sample	20 μL serum or plasma
ASSAY			
KEY /		Integral on board stability	8 weeks
		Calibrators availability	On board – positive and negative
		Calibration stability	4 weeks
		Controls availability	Positive and negative (60 tests per control kit – code 318841)
		Controls stability once opened	8 weeks
	_		

Performance Characteristics

- Cross-reactions: Zero cross reactions observed with a panel consisting of antibodies to hCMV, EBV, rubella virus, parvovirus B19, measles, Toxoplasma, HSV, VZV, HAV, Treponema, ANA
- Repeatability Coefficient of Variation: 3.9 7.2 %
- Reproducibility Coefficient of Variation (inter-site): 10.7 14.5 %

Diagnostic performance was assessed by testing 519 unselected specimens collected from a European laboratory routine (300 unselected individuals, 50 children ages 0-8 years, 130 subjects with serology suggestive of susceptibility to infection, 39 patients with serology suggestive of acute infection) against a commercially available reference EIA.

- **Diagnostic specificity**: 98.2% (164/167) (95% confidence interval: 94.8-99.6%)
- Diagnostic sensitivity: 98.5% (330/335) (95% confidence interval: 96.5-99.5%)

Ordering Information

LIAISON® Mumps IgG (Code 318840)	LIAISON® Control Mumps IgG (Code 318841)
LIAISON® Mumps IgM (Code 318830)	LIAISON® Control Mumps IgM (Code 318831)

AVAILABLE ON LIAISON® SYSTEMS

Product availability subject to required regulatory approval

